| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615720 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 6 Pages |
Abstract
A single-institutional retrospective analysis found no significant differences in the outcomes between GCLAC and CLAG for rrAML patients, although formal comparisons should be performed in a randomized clinical trial. The cost of GCLAC was greater than that of CLAG, which should be considered when evaluating the choice for the salvage chemotherapy options.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Benyam Muluneh, Kaitlyn Buhlinger, Allison M. Deal, Joshua F. Zeidner, Matthew C. Foster, Katarzyna Joanna Jamieson, Jill Bates, Hendrik W. Van Deventer,